Becton, Dickinson(NYSE) BDX

Becton, Dickinson and Company makes medical tools for hospitals and labs. Their products help doctors give medicine and take blood samples. These supplies help patients get the care they need worldwide.

Medicine and Monitoring

• Medical Essentials: Includes IV catheters, syringes, and blood collection tubes; generated $1.675 billion in revenue for the three months ended June 30, 2026.
• Connected Care: Offers automated medication dispensing systems and patient monitoring tools; generated $1.224 billion in revenue for the three months ended June 30, 2026.
• BioPharma Systems: Supplies prefillable drug delivery solutions to pharmaceutical companies; generated $670 million in revenue for the three months ended June 30, 2026.
• Interventional: Provides surgical tools and products for hernia repair and urology; generated $1.414 billion in revenue for the three months ended June 30, 2026.

Making Strategic Moves

• Completed the spin-off of the Biosciences and Diagnostic Solutions business on Feb. 9, 2026.
• Acquired the Advanced Patient Monitoring unit in the fourth quarter of fiscal year 2024.
• Reorganized the segment reporting structure into four distinct units effective Oct. 1, 2025.
• Launched the Excellence Unleashed strategy to focus on commercial capabilities and productivity.

Operational Strengths

The company sells products globally through independent distribution channels and direct sales representatives. It uses its BD Excellence operating model to drive continuous improvement and reduce manufacturing costs across its facilities.

A Look at the Finances

• Worldwide revenues reached $4.983 billion in the three months ended June 30, 2026, up 5.4% year over year.
• Cash flow from operating activities was $2.104 billion for the nine months ended June 30, 2026.
• The company returned $875 million to shareholders through dividends during the first nine months of fiscal year 2026.
• Total debt was $16.808 billion as of June 30, 2026, compared to $19.180 billion on Sept. 30, 2025.
• Share repurchases totaled $2.250 billion during the nine months ended June 30, 2026.

Bottom Line

Becton, Dickinson and Company has evolved into a more streamlined medical technology provider following the separation of its life sciences business. Its current strategy emphasizes innovation in drug delivery and surgical procedures to maintain its global market presence.